Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Mesenchymal stromal cells to promote kidney transplantation tolerance

Casiraghi, Federica; Remuzzi, Giuseppe; Perico, Norberto

Current Opinion in Organ Transplantation: February 2014 - Volume 19 - Issue 1 - p 47–53
doi: 10.1097/MOT.0000000000000035
STEM CELL TRANSPLANTATION: Edited by Giuseppe Remuzzi
Buy

Purpose of review Cell therapy with mesenchymal stromal cells (MSC) has emerged as a promising tolerance-inducing strategy, as MSC are potent modifiers of immune cells within adaptive as well as innate arm of the immune system. Here, we review recent evidence on both the beneficial and deleterious effect of MSC in experimental models of solid organ transplantation as well as first clinical experiences of MSC therapy in kidney transplant recipients.

Recent findings MSC are able to reprogram macrophages toward an anti-inflammatory phenotype capable to regulate antigraft immune response. This interaction is mediated mainly by TNF-α-induced-protein-6. Conversely, MSC also take on a proinflammatory phenotype and actually could worsen graft outcome. MSC in clinical transplantation is in its infancy and nobody so far has attempted to or provided evidence that this cell-based therapy is capable to promote operational tolerance. There are, however, supporting data of the ex-vivo immunoregulatory activity of MSC in treated patients.

Summary MSC have a great potential as a tolerance-promoting cell therapy. Extensive investigations are still needed to dissect the mechanism(s) of action of MSC, particularly in the setting of a proinflammatory environment, and to establish specific assays for monitoring MSC-treated patients to define the protolerogenic potential of MSC-based therapy in kidney transplantation.

Department of Clinical Immunology and Transplantation, Azienda Ospedaliera Papa Giovanni XXIII – IRCCS – Istituto di Ricerche Farmacologiche Mario Negri, Centro Ricerche Trapianti ‘Chiara Cucchi de Alessandri e Gilberto Crespi’, Bergamo, Italy

Correspondence to Giuseppe Remuzzi, MD, FRCP, IRCCS – Istituto di Ricerche Farmacologiche ‘Mario Negri’, Centro Anna Maria Astori, Science and Technology Park, Kilometro Rosso, Via Stezzano 87, 24126 Bergamo, Italy. Tel: +39 035421304; fax: +39 035319888; e-mail: giuseppe.remuzzi@marionegri.it

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins